The most important MS insight of the moment might not be about the immune system at all. It is about the virus that sits quietly in almost everyone: Epstein-Barr virus, or EBV. A study published in Science Translational Medicine (DOI: 10.1126/scitranslmed.adz6566) reports that in people with MS, the immune system is disproportionately targeting EBV proteins produced when the virus is actively replicating, not merely when it is dormant. The finding matters because it points to a different therapeutic lever: blocking the virus directly, with antivirals, instead of broadly suppressing or reshaping immune function.

Even more direct, the same team tracked CD4 T-cell responses before and after treatments that reduce the number of B-cells. Those treatments cut the EBV-specific T-cell response in MS almost down to levels seen in people without MS. At baseline, EBV was also detected as low levels in saliva of the MS patients, showing viral replication was happening in their bodies. After treatment, viral levels dropped below detectable levels in most people. In other words, when the body’s B-cell population gets reduced, signals tied to active EBV replication also get reduced. That is the bridge the paper is building toward antivirals.

To understand why this could be a big deal commercially and clinically, remember what MS therapy has been doing. MS is caused by an immune attack on myelin, the fatty sleeve wrapping nerves. When myelin is damaged, nerves transmit signals less effectively, which can cause symptoms such as muscle weakness. Many current drugs work by suppressing the immune system or altering immune components, which can slow progression. But broad immunosuppression also comes with tradeoffs, including an increased risk of infections. If EBV replication is a driver of the immune attack, then a more targeted antiviral strategy could theoretically deliver similar disease-modifying effects with fewer of those undesirable side effects.

The source of the viral hypothesis is not new, but the specificity is. EBV causes mononucleosis, also called glandular fever. Almost everyone is infected with EBV during childhood or teen years. The virus mainly infects B-cells, where it can remain dormant for the rest of a person’s life. The key puzzle has been the “why only some” problem: around 1 in 1000 people develop MS even though nearly everyone gets EBV. That discrepancy suggests there is something different about how the immune system responds to EBV in people who go on to develop MS.

In this study, investigators asked a straightforward question: in people with MS, what parts of EBV does the immune system respond to, and do those responses look different from people without MS? They focused on CD4 T-cells, which circulate in the body. While CD4 T-cells are not the cells that directly attack myelin, the paper notes multiple lines of evidence suggesting they play a role in MS. The researchers found that, in 30 people with MS, most of the CD4 T-cells targeting EBV were specifically targeting viral proteins produced when the virus is actively replicating, rather than proteins associated with the dormant stage. They also found that people with MS produced twice as many of these replication-targeting cells on average as 30 people without MS.

The study then pulled on another thread that matters for regulators and product strategy: treatment mechanism. Researchers looked at T-cells in 60 people with MS before and after drug treatments that reduce their number of B-cells. Those treatments reduced the T-cell response to EBV almost to the levels seen in people without MS. In addition, the team measured low levels of EBV in saliva of these participants before B-cell-reducing treatment, indicating ongoing replication. After treatment, EBV viral levels dropped below detectable levels in most participants.

Michael Levy, at Harvard Medical School, ties the logic together: B-cells are thought to help drive the harmful immune response in MS, which is why B-cell-depleting drugs have been effective. But these results suggest the same drugs may also work by eliminating B-cells infected with EBV, thereby reducing immune responses generated by active viral replication. Levy’s framing is blunt: “We’re thinking that depleting B-cells is also depleting the reservoir of the Epstein-Barr virus.” If that is true, targeting EBV directly with antivirals might be similarly effective, while potentially avoiding some side effects of therapies that weaken the immune system, such as increased infection risk.

That “maybe antivirals” conclusion immediately collides with real-world development math. The article notes there aren’t good EBV drugs currently available, but they can be developed, and Levy suggests this could become a useful specific therapy for MS in the future. Kjetil Bjornevik, at the Harvard T.H. Chan School of Public Health, says the idea is worth pursuing because EBV might represent a more specific target. He also points to market dynamics: Bjornevik says that if an antiviral had a similar effect as the most effective MS drugs, there would be a big market for that antiviral. There is already another technology path in flight, too: CAR T-cell therapy, using modified immune cells that can temporarily eliminate B-cells altogether. Dozens of people with MS have gone into remission after CAR-T treatment, Levy says, but he also warns about possible recurrence as EBV persists elsewhere and reinfects B-cells as they slowly recover in the years after CAR-T treatment. In that scenario, antivirals might be needed, meaning the strategy becomes a combination or sequencing question rather than a simple replacement.

For executives, the second-order implication is not just scientific curiosity. It is about how to design trials, position risk, and communicate with regulators in a disease category where safety signals have outsized impact. The article also notes EBV vaccines are under development, with Natalia Drosu at Massachusetts General Hospital saying if people do not get infected with EBV, their risk of MS would be virtually zero. But Levy points out a public-health feasibility constraint: 1000 people would have to be vaccinated to prevent just one case of MS, so it is not clear if EBV would be justified for preventing MS alone, even though EBV causes other problems including cancers and is linked to other autoimmune conditions such as lupus and rheumatoid arthritis.

For peers watching this space, the strategic stake is simple: MS therapy is crowded, safety requirements are strict, and mechanisms matter for differentiation. This study argues that active EBV replication is part of the immune story in MS, and that B-cell-depleting treatments may be working partly by removing an EBV replication reservoir. If future trials confirm that an antiviral can reproduce that effect, the product category could shift from “manage the immune system” to “shut down the trigger the immune system is reacting to.” That is a different clinical narrative, a different regulatory posture, and potentially a very different competitive map.